레플리문 그룹(REPL)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $13.07 (+1.55%), 시가총액 $0.43B, 52주 최저~최고 $1.70 ~ $12.63.
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF for a range of solid tumors. The company is also developing RP2 that express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3, which express immune-activating proteins that stimulate T cells. Replimune Group
레플리문 그룹의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
레플리문 그룹의 현재 주가는 $13.07 (+1.55%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
레플리문 그룹의 시가총액은 약 $0.43B입니다.
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer. The company's proprietary oncolytic immuno